Core Viewpoint - The article highlights the explosive growth of the weight loss drug sector, particularly focusing on the recent IPO of Silverno Pharmaceuticals, which has significantly impacted related stocks in both the Hong Kong and A-share markets [4][8]. Group 1: Market Performance - Silverno Pharmaceuticals saw a staggering 206% increase on its first trading day, reaching a market capitalization of over HKD 26 billion, making it one of the hottest IPOs of 2025 [4][6]. - Other related stocks such as Pigeon BioPharma surged by 32.45%, while both Jiuyuan Gene and Gilead Pharmaceuticals experienced gains exceeding 10% [4][8]. - In the A-share market, stocks like Borui Pharmaceuticals, Changshan Pharmaceutical, and Shengnuo Bio have all doubled in value this year, with Zhongsheng Pharmaceuticals up by 88.43% [4][11]. Group 2: Company Highlights - Silverno Pharmaceuticals, established in 2014, focuses on innovative therapies for diabetes and metabolic diseases, with its core product, Isupatide α, recently approved for the treatment of type 2 diabetes in China [6][8]. - The company reported revenue of CNY 38.144 million from Isupatide α sales within just four months of its launch [6]. - Pigeon BioPharma, which has been listed since May 27, has seen its stock price increase by 105% since its IPO, focusing on innovative therapies for chronic diseases [7][10]. Group 3: Industry Outlook - The global obesity issue has made weight loss drugs a "golden track" in the pharmaceutical industry, with both Hong Kong and A-share markets witnessing a surge in related stocks [8]. - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, with significant opportunities for domestic oral weight loss drugs [14]. - Companies like Borui Pharmaceuticals, Lianbang Pharmaceutical, and Gilead Pharmaceuticals are expected to emerge as major players in the market, driven by their innovative drug development and commercialization capabilities [14].

Core Insights - The market for weight loss drugs is gaining significant attention, with companies like Silverno Pharmaceuticals and others experiencing substantial stock price increases [1][5][11] - Silverno Pharmaceuticals has seen a remarkable IPO performance, with a 5341.66 times oversubscription and a market capitalization exceeding HKD 26 billion [3] - The overall performance of weight loss-related stocks in both Hong Kong and A-share markets has been strong, with several companies reporting over 100% gains this year [5][8] Company Performance - Silverno Pharmaceuticals' core product, Isupaglutide α, has generated revenue of approximately CNY 38.14 million within four months of its launch in China [3] - Other companies like Pag Biopharma and Songli Pharmaceutical have also seen significant stock price increases, with Pag Biopharma rising 32.45% and Songli Pharmaceutical increasing by 13.72% [4][5] - In the A-share market, companies such as Borui Pharmaceutical and Changshan Pharmaceutical have reported gains of 280% and over 100%, respectively [8][10] Market Trends - The global obesity issue is driving the demand for weight loss drugs, positioning this sector as a "golden track" in the pharmaceutical industry [5] - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, highlighting the potential for domestic oral weight loss drugs [11] - Companies with strong research and sales capabilities are expected to dominate the commercialization of weight loss drugs, with a focus on those with advanced R&D progress [11]

Group 1 - Silver诺医药's IPO on August 15 saw a surge of 206%, reaching a market capitalization of over HKD 26 billion, marking it as one of the hottest IPOs of 2025 [2][3] - The market is increasingly focused on the weight loss drug sector, with related stocks in both Hong Kong and A-shares experiencing significant attention and price increases [2][5] - Silver诺医药's core product, Isu-Paglutide α, is a long-acting GLP-1 receptor agonist approved in China for treating type 2 diabetes, with ongoing clinical trials for obesity treatment [3][4] Group 2 - The stock price of other weight loss concept stocks, such as PegBio, surged by 32.45%, and it has seen a cumulative increase of 105% since its listing on May 27 [4][5] - Other notable performers include GeneTech, which rose nearly 23% on August 15, and has seen a cumulative increase of 131% this year, driven by its potential first domestic Semaglutide biosimilar [6] - A-share companies like Borui Pharmaceutical and Changshan Pharmaceutical have also seen significant gains, with Borui's stock price increasing by 280% this year [6] Group 3 - Analysts predict that the GLP-1 drug market could exceed USD 150 billion by 2030, with a compound annual growth rate of 20%, highlighting the potential for domestic oral weight loss drugs [7] - Companies with strong sales capabilities and advanced R&D progress are expected to dominate the commercialization competition in the GLP-1 sector [7]

格隆汇8月15日丨歌礼制药-B(1672.HK)在港交所发布中期业绩报告，上半年收入1.04亿元，同比增加 111.4%；净亏损8795.1万元，同比收窄32.5%。 ...

每经AI快讯，8月15日，歌礼制药-B(01672.HK)在港交所发布中期业绩报告，上半年收入1.04亿元，同 比增加111.4%；净亏损8795.1万元，同比收窄32.5%。 ...

Core Viewpoint - The company reported significant revenue growth and advancements in its drug pipeline, particularly in obesity treatment, indicating strong research and development capabilities and a commitment to addressing unmet clinical needs [1][2]. Financial Performance - Total revenue reached RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, up 10.9% year-on-year [1] - Loss attributable to equity shareholders was RMB 87.95 million, a decrease of 32.5% compared to the previous year [1] - Loss per share was 9.14 cents [1] Drug Development Progress - ASC30, an oral medication for obesity, showed a significant average weight reduction of 6.5% after 28 days in a U.S. Phase Ib study, positioning it as a potential best-in-class treatment for obesity [1] - The company rapidly enrolled 125 participants in a U.S. Phase IIa study for ASC30, demonstrating efficient execution in clinical trials [2] - ASC30 also showed a 36-day half-life in a single subcutaneous injection study, supporting less frequent dosing [2] - ASC47, another obesity treatment, exhibited a 40-day half-life and has completed participant enrollment for a study combining it with semaglutide [2] - ASC50, an oral IL-17 inhibitor, has entered Phase I clinical trials with initial dosing completed [2] - ASC40, a daily oral FASN inhibitor for acne treatment, demonstrated statistically significant improvements in all primary and secondary endpoints in a Phase III study, indicating its potential for a breakthrough in acne treatment [2] Research and Development Commitment - The achievements highlight the company's strong R&D capabilities and commitment to developing best-in-class and first-in-class drugs to meet long-term clinical needs [2]

Investment Rating - The report assigns a "Buy" investment rating for the company, indicating a positive outlook for its stock performance [11]. Core Insights - The company is making rapid progress in its clinical trials, particularly with its small molecule GLP-1R agonist ASC30, which has shown promising results in weight loss and safety [6][7]. - ASC30 is positioned to potentially become a "Best in Class" treatment due to its efficacy in weight reduction and low adverse effects [7]. - The company is also developing ASC47, a small molecule THRβ agonist, which is expected to work synergistically with GLP-1 treatments to enhance weight loss while minimizing muscle loss [8]. Clinical Development - The company initiated its first phase IIa clinical trial for ASC30 in early July, successfully enrolling 125 participants within a month [6]. - The expected timeline for top-line data from the ASC30 trial is Q4 2025 [6]. Financial Projections - The report forecasts the company's R&D expenses to increase to 415 million, 487 million, and 540 million RMB for the years 2025 to 2027, respectively [9]. - The projected net profit attributable to the parent company is expected to be -372.9 million, -467.09 million, and -562.67 million RMB for the years 2025 to 2027 [9][13]. - Revenue projections for 2021 to 2023 are not specified, but the report indicates a significant decline in revenue for 2024 [9][13]. Financial Statements Overview - The company's total assets are projected to decrease from 2,491.01 million RMB in 2023 to 571.46 million RMB by 2027 [14][16]. - The report highlights a significant drop in operating income, with a forecast of 1.28 million RMB in 2024 and no revenue expected in 2025 and 2026 [13][16]. - The cash flow statement indicates negative cash flow from operating activities, with projections of -555.17 million RMB in 2025 [15].

Core Viewpoint - The company reported significant revenue growth and advancements in its drug pipeline, particularly in obesity treatment, indicating strong research and development capabilities and a commitment to addressing unmet clinical needs [1][2]. Financial Performance - The company achieved total revenue of RMB 104 million, representing a year-on-year increase of 111.4% [1] - Research and development costs amounted to RMB 147 million, reflecting a year-on-year increase of 10.9% [1] - The loss attributable to equity shareholders was RMB 87.95 million, a decrease of 32.5% year-on-year [1] - The loss per share was 9.14 cents [1] Drug Development Progress - The ASC30 oral tablet for obesity showed a significant average weight reduction of up to 6.5% after 28 days of treatment in a U.S. Phase Ib study, positioning it as a potential best-in-class candidate for obesity treatment [1] - The company rapidly enrolled 125 participants in a U.S. Phase IIa study for ASC30, demonstrating efficient execution in clinical trials [2] - ASC30 also showed a 36-day half-life in a single subcutaneous injection study, supporting less frequent dosing [2] - ASC47, another obesity treatment, demonstrated a 40-day half-life and has completed participant enrollment for a combination study with semaglutide [2] - ASC50, an oral small molecule IL-17 inhibitor, has completed initial dosing in a U.S. Phase I clinical study [2] - The FASN inhibitor, denifasirt, showed statistically significant improvements in all primary and secondary endpoints in a Phase III study for acne treatment, indicating its potential for a major breakthrough in acne therapy [2]

[Financial Summary](index=1&type=section&id=%E8%B4%A2%E5%8A%A1%E6%A6%82%E8%A6%81) Provides a concise overview of the company's financial performance for the six months ended June 30, 2025 Financial Summary for the Six Months Ended June 30, 2025 (Unaudited) | Metric | For the Six Months Ended June 30 (Unaudited) | Change (%) | | :--- | :--- | :--- | | | **2025 (RMB thousands)** | **2024 (RMB thousands)** | | | **Total Revenue** | 103,577 | 49,004 | 111.4% | | **R&D Costs** | (146,812) | (132,382) | 10.9% | | **Administrative Expenses** | (43,302) | (41,356) | 4.7% | | **Loss Before Tax** | (87,951) | (130,318) | -32.5% | | **Loss for the Period** | (87,951) | (130,318) | -32.5% | | **Loss Per Share (Basic and Diluted)** | (9.14) cents | (12.82) cents | -28.7% | [Company Overview and Business Progress](index=2&type=section&id=%E5%85%AC%E5%8F%B8%E6%A6%82%E8%A7%88%E4%B8%8E%E4%B8%9A%E5%8A%A1%E8%BF%9B%E5%B1%95) Details the company's strategic vision, overall business advancements, and pipeline development across key therapeutic areas [Company Profile and Vision](index=2&type=section&id=%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E4%B8%8E%E6%84%BF%E6%99%AF) Ascletis aims to be a world-class innovative biopharmaceutical company addressing unmet global medical needs in metabolic diseases - Company vision: To be the most innovative world-class biopharmaceutical company, dedicated to addressing unmet global medical needs in metabolic diseases[5](index=5&type=chunk) [Overall Business Overview](index=2&type=section&id=%E6%95%B4%E4%BD%93%E4%B8%9A%E5%8A%A1%E6%A6%82%E8%A7%88) The company made significant pipeline progress in metabolic and immune diseases, narrowing its loss for the period despite increased R&D investment - The company achieved significant progress in its R&D pipeline across multiple disease areas, including: - **Obesity treatment**: ASC30 oral tablet showed up to **6.5% weight loss** in a US Ib study; ASC30 subcutaneous formulation had a half-life of 36 days, supporting monthly dosing; muscle-sparing candidate ASC47 completed enrollment for combination study with semaglutide - **Immune diseases**: Oral small molecule IL-17 inhibitor ASC50 initiated Phase I clinical study in the US - **Expanded indications**: FASN inhibitor denifanstat (ASC40) for acne achieved all primary endpoints in Phase III study[6](index=6&type=chunk) Financial Performance and Cash Position | Metric | 2025 H1 | 2024 H1 | Change | | :--- | :--- | :--- | :--- | | **Loss for the Period** | approx. 88.0 million RMB | approx. 130.3 million RMB | -32.5% | | **R&D Costs** | approx. 146.8 million RMB | approx. 132.4 million RMB | +10.9% | | **Cash and Equivalents** | approx. 1,827.9 million RMB | approx. 2,117.2 million RMB | - | - As of June 30, 2025, the Group's cash and equivalents reserves were approximately **1.828 billion RMB**, projected to support R&D and operations until 2029[7](index=7&type=chunk) [R&D Pipeline](index=3&type=section&id=%E7%A0%94%E5%8F%91%E7%AE%A1%E7%BA%BF) The company maintains three core pipelines: metabolic diseases, immune diseases, and expanded indications, with global or Greater China rights for various drug candidates - **Metabolic Disease Pipeline**: Core products for obesity, ASC30 (oral/subcutaneous) and ASC47 (subcutaneous), both with global rights and in clinical Phase IIa or Ib[8](index=8&type=chunk) - **Immune Disease Pipeline**: Core product, oral small molecule IL-17 inhibitor ASC50, for psoriasis and other immune diseases, with global rights, in clinical Phase I[9](index=9&type=chunk) - **Expanded Indication Pipeline**: Core product, oral small molecule FASN inhibitor ASC40, for acne, with Greater China rights, in Phase III[10](index=10&type=chunk) [Management Discussion and Analysis](index=4&type=section&id=%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) Provides an in-depth review of the company's operational performance, financial results, and future outlook [Business Review](index=4&type=section&id=%E4%B8%9A%E5%8A%A1%E5%9B%9E%E9%A1%BE) The company detailed clinical progress and key data for its core pipeline products, with notable advancements in metabolic disease drugs and strategic project adjustments [Metabolic Diseases](index=4&type=section&id=%E4%BB%A3%E8%B0%A2%E6%80%A7%E7%96%BE%E7%97%85) Significant progress in obesity drug pipeline, with ASC30 showing up to 6.5% weight loss and ASC47 demonstrating potential for healthy weight reduction - **ASC30 Oral Tablet**: In a US Phase Ib study, after 4 weeks of treatment, the placebo-adjusted average weight loss was up to **6.5%**, with good tolerability. Its 13-week Phase IIa study has completed enrollment of 125 patients, with top-line data expected in Q4 2025[13](index=13&type=chunk)[14](index=14&type=chunk) - **ASC30 Subcutaneous Injection**: In a US Phase Ib study, an ultra-long-acting formulation showed a half-life of **36 days** in obese patients, supporting monthly or less frequent dosing. Phase IIa study has completed dosing of the first subjects[16](index=16&type=chunk)[17](index=17&type=chunk) - **ASC47 (Muscle-Sparing)**: A single subcutaneous injection in obese patients showed a half-life of **40 days**, supporting monthly to bi-monthly dosing. The combination study with semaglutide has completed enrollment of all 28 subjects[18](index=18&type=chunk)[19](index=19&type=chunk) [Immune Diseases](index=6&type=section&id=%E5%85%8D%E7%96%AB%E7%96%BE%E7%97%85) The company's self-developed novel oral small molecule IL-17 inhibitor ASC50 has initiated a Phase I clinical trial in the US for psoriasis - The novel oral small molecule IL-17 inhibitor **ASC50** has initiated a Phase I clinical trial in the US for psoriasis, with potential to be a best-in-class daily oral drug[21](index=21&type=chunk) - ASC50 is the company's first immunology candidate developed through its structure-based **AI-assisted drug discovery (AISBDD) platform**[22](index=22&type=chunk) [Expanded Indications and Others](index=7&type=section&id=%E6%8B%93%E5%B1%95%E6%80%A7%E9%80%82%E5%BA%94%E7%97%87%E5%8F%8A%E5%85%B6%E4%BB%96) FASN inhibitor denifanstat (ASC40) successfully completed Phase III trials for acne, while the rGBM project was terminated, and out-licensing opportunities are being sought for other assets - **ASC40 for Acne**: Phase III clinical trial achieved success, with all endpoints showing highly statistically significant improvements and good safety. Efficacy was superior to FDA-approved drugs like sarecycline and doxycycline. The company plans to seek commercial partnerships in 2025[24](index=24&type=chunk)[25](index=25&type=chunk)[26](index=26&type=chunk) - **Project Termination and Out-licensing**: Based on study results, the company decided to terminate the ASC40 project for recurrent glioblastoma (rGBM). For ASC40 in MASH and ASC61 for solid tumors, the company will seek opportunities to maximize project value, including out-licensing[27](index=27&type=chunk)[28](index=28&type=chunk)[30](index=30&type=chunk) [Preclinical Discovery](index=8&type=section&id=%E4%B8%B4%E5%BA%8A%E5%89%8D%E5%8F%91%E7%8E%B0) The company continues to leverage its AI-assisted drug discovery (AISBDD) and ultra-long-acting drug development (ULAP) platforms to strengthen early-stage R&D - The company continues to strengthen early-stage discovery by leveraging its two core platforms (AISBDD and ULAP) to develop more globally competitive small molecule and peptide pipeline products[31](index=31&type=chunk) [Future and Outlook](index=9&type=section&id=%E6%9C%AA%E6%9D%A5%E5%8F%8A%E5%89%8D%E6%99%AF) The company's H2 2025 strategy focuses on advancing core clinical programs, obtaining key data, strengthening early R&D, and pursuing out-licensing opportunities - Key Outlook for H2 2025: - **Obtain Key Clinical Data**: Expected top-line data from US clinical studies for ASC30 oral tablet (obesity), ASC47 combination therapy (obesity), and ASC50 (psoriasis) - **Advance Clinical Enrollment**: Complete enrollment for all subjects in the US Phase IIa study of ASC30 monthly subcutaneous injection (obesity) - **Strengthen Early R&D**: Accelerate peptide pipeline clinical trials using the ULAP platform - **Seek Out-licensing**: Actively pursue collaboration opportunities with global pharmaceutical companies[35](index=35&type=chunk) [Financial Position Analysis](index=10&type=section&id=%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) The company's total revenue increased significantly, driven by fair value gains and government grants, while R&D expenses rose, and financial ratios improved, indicating a robust financial position [Revenue and Other Income](index=10&type=section&id=%E6%94%B6%E5%85%A5%E4%B8%8E%E6%94%B6%E7%9B%8A) Total revenue increased by 111.4% to 103.6 million RMB, primarily due to higher fair value gains from financial assets and increased government grants - Total revenue (revenue, other income and gains) increased by **111.4%** from **49.0 million RMB** to **103.6 million RMB**, primarily due to an increase in other income and gains[37](index=37&type=chunk) Details of Other Income and Gains (RMB thousands) | Item | 2025 H1 | 2024 H1 | | :--- | :--- | :--- | | Bank interest income | 30,037 | 48,076 | | Government grants | 34,175 | 12,226 | | Net fair value gain/(loss) on financial assets | 39,151 | (10,735) | | Gain on dilution of interest in an associate | – | 21,147 | | Loss on remeasurement of interest in an associate | – | (24,546) | | **Total** | **102,496** | **49,004** | [Costs and Expenses](index=11&type=section&id=%E6%88%90%E6%9C%AC%E4%B8%8E%E5%BC%80%E6%94%AF) R&D expenses increased by 10.9% to 146.8 million RMB, mainly due to increased investment in the metabolic disease pipeline, while administrative expenses slightly rose - R&D expenses increased by **10.9%** to **146.8 million RMB**, primarily due to increased investment in the metabolic disease product pipeline[43](index=43&type=chunk)[44](index=44&type=chunk) R&D Costs by Product Pipeline (RMB thousands) | Product Pipeline | 2025 H1 | 2024 H1 | | :--- | :--- | :--- | | Metabolic Diseases | 42,640 | 27,037 | | Expanded Indications - Acne | 43,970 | 47,182 | | Expanded Indications - Oncology | 15,259 | 15,807 | | Preclinical | 38,023 | 14,486 | | **Total** | **146,812** | **132,382** | - Administrative expenses increased by **4.7%** to **43.3 million RMB**, primarily due to higher staff costs and benefits[41](index=41&type=chunk)[42](index=42&type=chunk) [Key Balance Sheet Items](index=13&type=section&id=%E5%85%B3%E9%94%AE%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8%E9%A1%B9%E7%9B%AE) Inventories, trade receivables, and financial assets increased, with non-current financial assets significantly rising due to fair value gains on listed equity securities, while other payables decreased - Non-current financial assets at fair value through profit or loss increased from **53.5 million RMB** to **79.3 million RMB**, primarily due to an increase in the fair value of investments in NASDAQ-listed equity securities[59](index=59&type=chunk) - Total other payables and accrued expenses decreased from **145.2 million RMB** to **119.9 million RMB**, with provisions reduced by **11.2 million RMB** due to arbitration settlement[64](index=64&type=chunk)[66](index=66&type=chunk) [Liquidity and Capital Resources](index=18&type=section&id=%E6%B5%81%E5%8A%A8%E8%B5%84%E9%87%91%E4%B8%8E%E8%B5%84%E6%9C%AC%E8%B5%84%E6%BA%90) The company held 1.828 billion RMB in cash and equivalents, with net cash outflow from operating activities and net inflow from investing activities, primarily from maturing time deposits Condensed Consolidated Cash Flow Statement Summary (RMB thousands) | Item | 2025 H1 | 2024 H1 | | :--- | :--- | :--- | | Net cash flow (used in) operating activities | (172,990) | (203,415) | | Net cash flow from investing activities | 904,605 | 261,633 | | Net cash flow (used in) financing activities | (14,485) | (45,455) | | **Net increase in cash and cash equivalents** | **717,130** | **12,763** | - Net cash inflow from investing activities was primarily due to a decrease of approximately **864 million RMB** in time deposits with original maturity over three months[71](index=71&type=chunk) - Net cash outflow from financing activities was primarily due to share repurchases totaling approximately **12.8 million RMB**[72](index=72&type=chunk) [Key Financial Ratios](index=22&type=section&id=%E5%85%B3%E9%94%AE%E8%B4%A2%E5%8A%A1%E6%AF%94%E7%8E%87) The company's liquidity improved, with current and quick ratios increasing, and the debt-to-asset ratio decreasing, indicating a more robust financial structure Key Financial Ratios | Ratio | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Current Ratio | 14.6 | 12.9 | | Quick Ratio | 14.5 | 12.8 | | Debt-to-Asset Ratio | 6.5% | 7.5% | - The increase in current and quick ratios and the decrease in the debt-to-asset ratio were primarily due to a **reduction in current liabilities**[82](index=82&type=chunk) [Other Information](index=21&type=section&id=%E5%85%B6%E4%BB%96%E4%BF%A1%E6%81%AF) The company disclosed litigation updates with Viking Therapeutics, including provisions for ITC fines, and detailed its employee structure and compensation policy [Litigation and Contingent Liabilities](index=21&type=section&id=%E8%AF%89%E8%AE%BC%E4%B8%8E%E6%88%96%E7%84%B6%E8%B4%9F%E5%80%BA) The company disclosed litigation with Viking Therapeutics, making provisions for an ITC fine of approximately $567,000 while actively defending the ongoing USDC lawsuit - Regarding the litigation with Viking Therapeutics, the ITC's recommended judgment imposed a fine of approximately **$567,000**, for which the company has made provisions[76](index=76&type=chunk) - The lawsuit filed with the USDC is ongoing, and the company will actively defend it, with no provisions made as of the end of the reporting period[77](index=77&type=chunk) [Employees and Remuneration Policy](index=23&type=section&id=%E9%9B%87%E5%91%98%E5%8F%8A%E8%96%AA%E9%85%AC%E6%94%BF%E7%AD%96) As of June 30, 2025, the Group had 208 employees, with 65.9% in R&D, reflecting its research-centric strategy, and total employee costs increased Number of Employees by Function (as of June 30, 2025) | Function | Number of Employees | % of Total | | :--- | :--- | :--- | | Management | 4 | 1.9% | | R&D | 137 | 65.9% | | Manufacturing | 29 | 13.9% | | Operations | 38 | 18.3% | | **Total** | **208** | **100.0%** | - For the six months ended June 30, 2025, total employee costs were approximately **82.1 million RMB**, compared to **76.8 million RMB** in the prior period[84](index=84&type=chunk) [Consolidated Financial Statements](index=24&type=section&id=%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) Presents the company's consolidated financial performance and position, including the income statement and balance sheet [Consolidated Statement of Profit or Loss](index=24&type=section&id=%E7%BB%BC%E5%90%88%E6%8D%9F%E7%9B%8A%E8%A1%A8) For the six months ended June 30, 2025, the company reported revenue of 1.08 million RMB and a loss of 87.95 million RMB, a 32.5% reduction from the prior year Summary of Consolidated Statement of Profit or Loss (RMB thousands) | Item | 2025 H1 | 2024 H1 | | :--- | :--- | :--- | | Revenue | 1,081 | – | | Other income and gains | 102,496 | 49,004 | | R&D costs | (146,812) | (132,382) | | Administrative expenses | (43,302) | (41,356) | | **Loss before tax** | **(87,951)** | **(130,318)** | | **Loss for the period** | **(87,951)** | **(130,318)** | [Consolidated Statement of Financial Position](index=26&type=section&id=%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E8%A1%A8) As of June 30, 2025, the company reported total assets of 1.997 billion RMB, total liabilities of 129.0 million RMB, and net assets of 1.868 billion RMB, indicating strong liquidity Summary of Consolidated Statement of Financial Position (RMB thousands) | Item | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total non-current assets** | 173,899 | 153,790 | | **Total current assets** | 1,822,936 | 1,970,782 | | **Total assets** | **1,996,835** | **2,124,572** | | **Total current liabilities** | 125,125 | 153,053 | | **Total non-current liabilities** | 3,873 | 5,357 | | **Total liabilities** | **129,000** | **158,410** | | **Net assets** | **1,867,837** | **1,966,162** | [Notes to Interim Financial Report](index=28&type=section&id=%E4%B8%AD%E6%9C%9F%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A%E9%99%84%E6%B3%A8) Provides detailed explanations and disclosures supporting the interim financial statements, covering accounting policies, revenue, capital, and dividends [Company Information and Basis of Preparation](index=28&type=section&id=%E5%85%AC%E5%8F%B8%E8%B5%84%E6%96%99%E4%B8%8E%E7%BC%96%E8%A3%BD%E5%9F%BA%E5%87%86) This unaudited interim financial report, reviewed by KPMG, details the company's primary engagement in drug R&D and its listing on the HKEX - This interim financial report is unaudited but has been reviewed by **KPMG** in accordance with Hong Kong Standard on Review Engagements 2410[96](index=96&type=chunk) - The company is an investment holding company, with subsidiaries primarily engaged in drug R&D. Its shares were listed on the Main Board of the Stock Exchange of Hong Kong on August 1, 2018[93](index=93&type=chunk)[94](index=94&type=chunk) [Revenue and Segment Reporting](index=29&type=section&id=%E6%94%B6%E5%85%A5%E5%8F%8A%E5%88%86%E9%83%A8%E6%8A%A5%E5%91%8A) Revenue for the period was 1.08 million RMB, primarily from R&D services, with the company managed as a single operating segment and revenue mainly from Hong Kong - Revenue for the reporting period was **1,081 thousand RMB**, primarily from providing R&D services (**1,054 thousand RMB**)[100](index=100&type=chunk) - The company operates as a **single operating segment**, thus no segment information is presented[102](index=102&type=chunk) [Capital, Reserves and Dividends](index=33&type=section&id=%E8%B5%84%E6%9C%AC%E3%80%81%E5%82%A8%E5%A4%87%E5%8F%8A%E8%82%A1%E6%81%AF) The board did not recommend an interim dividend, while the company repurchased 3.44 million shares and issued new shares from option exercises, also canceling repurchased shares - The Board does not recommend the payment of any dividend for the six months ended June 30, 2025[113](index=113&type=chunk) - During the interim period, the company repurchased shares on the Stock Exchange of Hong Kong for a total consideration of **13.81 million HKD** (equivalent to **12.76 million RMB**)[115](index=115&type=chunk) - During the reporting period, the company cancelled **44,896,790 shares**[117](index=117&type=chunk) [Other Disclosure Information](index=35&type=section&id=%E5%85%B6%E4%BB%96%E6%8A%AB%E9%9C%B2%E4%BF%A1%E6%81%AF) Covers corporate governance practices, details of securities transactions including share repurchases, and the review process for interim results [Corporate Governance](index=35&type=section&id=%E4%BC%81%E4%B8%9A%E7%AE%A1%E6%B2%BB) The company adheres to the Corporate Governance Code, with the only deviation being Dr. Wu holding both Chairman and CEO roles for efficient leadership - The company has complied with the Corporate Governance Code during the reporting period, except that the roles of Chairman and Chief Executive Officer are not separate, both held by Dr. Wu. The Board believes this arrangement provides more efficient leadership[120](index=120&type=chunk) [Securities Transactions and Share Repurchases](index=35&type=section&id=%E8%AF%81%E5%88%B8%E4%BA%A4%E6%98%93%E4%B8%8E%E8%82%A1%E4%BB%BD%E5%9B%9E%E8%B4%AD) The company repurchased 3.44 million shares for 13.559 million HKD to enhance shareholder value and holds treasury shares for its share award scheme Details of Share Repurchases During the Reporting Period | Month of Transaction | Number of Shares Repurchased | Highest Price Per Share (HKD) | Lowest Price Per Share (HKD) | Total Consideration (HKD) | | :--- | :--- | :--- | :--- | :--- | | January 2025 | 2,640,000 | 4.13 | 2.94 | 9,301,470.00 | | April 2025 | 800,000 | 6.74 | 4.57 | 4,257,980.00 | - As of June 30, 2025, the company held **5,784,210 treasury shares** for its 2025 share award scheme[123](index=123&type=chunk) [Review of Interim Results](index=36&type=section&id=%E4%B8%AD%E6%9C%9F%E4%B8%9A%E7%BB%A9%E5%AE%A1%E9%98%85) KPMG, the independent auditor, reviewed the interim financial information, and the Audit Committee confirmed its compliance with accounting standards and regulations - The company's independent auditor, **KPMG**, has reviewed the interim financial information[125](index=125&type=chunk) - The Audit Committee, comprising three independent non-executive directors, has reviewed the interim results and found them to be in compliance with applicable accounting standards and regulations[125](index=125&type=chunk)

Core Insights - The GLP-1 market is transitioning from a phase of broad growth to a more refined development stage, emphasizing efficacy, safety, convenience, and economic factors [1][2] - Recent stock price volatility for major players like Novo Nordisk and Eli Lilly reflects heightened competition and market expectations [1][3] Group 1: Market Dynamics - Novo Nordisk lowered its 2025 revenue and profit growth forecasts, with sales growth now expected between 8-14% and operating profit growth between 10-16%, leading to a stock drop of over 20% [1][2] - Eli Lilly's stock fell over 14% after disappointing data from its oral GLP-1 drug Orforglipron, despite strong overall quarterly results [2][3] Group 2: Competitive Landscape - The competition in the GLP-1 sector is intensifying, with increased pressure from rival products and combination therapies [2][3] - Eli Lilly's Zepbound faced negative impacts after being excluded from CVS's standard prescription drug list, highlighting the importance of insurance coverage and pharmacy benefit management (PBM) access [3][4] Group 3: Strategic Opportunities - Domestic companies are focusing on three key areas for growth: multi-target exploration, cross-indication expansion, and iterative upgrades in efficacy and safety [6][7] - The success of dual-target drugs like Tirzepatide has validated the multi-target approach, while new therapeutic areas such as cardiovascular events and neurodegenerative diseases present additional opportunities [6][7] Group 4: Domestic Market Trends - Domestic GLP-1 products are increasingly utilizing e-commerce platforms for distribution, alongside traditional hospital channels [5][6] - Companies like Hengrui Medicine are advancing in the dual-target GLP-1 space, with promising clinical results for their products [7]